From the Guidelines
Common side effects of Monjaro are not explicitly mentioned in the provided evidence, however, based on the available information, it can be inferred that the question might be referring to a different medication or the evidence provided does not directly relate to Monjaro. Given the information provided in the evidence, it appears to be focused on medications for asthma and their potential side effects, such as cromolyn, nedocromil, omalizumab, montelukast, zafirlukast, zileuton, and theophylline 1. Some common side effects mentioned for these medications include:
- Unpleasant taste from nedocromil in 15% to 20% of patients
- Anaphylaxis reported in 0.2% of patients treated with omalizumab
- Pain and bruising of injection sites in 5% to 20% of patients receiving omalizumab
- Rare cases of Churg-Strauss with montelukast, though the association is unclear
- Reversible hepatitis and, rarely, irreversible hepatic failure with zafirlukast
- Elevation of liver enzymes, and limited case reports of reversible hepatitis and hyperbilirubinemia with zileuton
- Dose-related acute toxicities and adverse effects at usual therapeutic doses with theophylline, including tachycardia, nausea, vomiting, tachyarrhythmias, central nervous system stimulation, headache, seizures, hematemesis, hyperglycemia, hypokalemia, insomnia, gastric upset, and increase in hyperactivity in some children. It's essential to consult the prescribing information or a healthcare professional for the specific side effects associated with Monjaro, as the provided evidence does not directly address this medication.
From the Research
Common Side Effects of Monjaro
There are no research papers to assist in answering this question, as the provided studies do not mention Monjaro or its side effects.
- The studies provided focus on various topics such as the efficacy and safety of efgartigimod in elderly patients with generalized myasthenia gravis 2, the immune response during sepsis 3, the global prevalence of child and adolescent overweight and obesity 4, and the regulation of non-canonical autophagy in cancer cells with RAS mutations 5.
- None of these studies mention Monjaro, and therefore, there is no available evidence to provide information on its common side effects.